THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [S3-BKLG-25] ID: TIP-MED-000485 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Noradrenaline (Norepinephrine) Tartrate IP

Active Ingredient / Scientific Identity: Noradrenaline • Class: Stage 3 Hospital Critical-Care, Parenteral ICU & UIP Immunisation Module

⚖️ Compare Profile
Generic / Entity NameNoradrenaline (Norepinephrine) Tartrate IP ([S3-BKLG-25])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassStage 3 Hospital Critical-Care, Parenteral ICU & UIP Immunisation Module
Available Dosage FormsRefer to approved institutional protocol & product label
Regulatory ClassificationSchedule H / Specialist Hospital Prescription Only (Drugs Rules, 1945)
Key Warning & Review DateRequires specialist oncology/critical-care dosing verification, BSA/weight protocol validation, and CDSCO statutory review pr
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H / Specialist Hospital Prescription Only (🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Noradrenaline (Norepinephrine) Tartrate IP (TIP-MED-000485, Reference Code [S3-BKLG-25]) is classified under Emergency & Toxicology) as a Stage 3 Hospital Critical-Care, Parenteral ICU & UIP Immunisation Module. Within the Indian regulatory and compendial framework, it is governed under Schedule H / Specialist Hospital Prescription Only (Drugs Rules, 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed with Deferred to Dedicated Stage 3 Specialist Module (Not in Ch 03–12). Generic reference only; verify institutional oncology/ICU label.
Co-indexed with Deferred to Dedicated Stage 3 Specialist Module (Not in Ch 03–12). Generic reference only; verify institutional oncology/ICU label.
Dosage Forms & Available Strengths:
Refer to approved institutional protocol & product label
Routes: Intravenous / Subcutaneous / Intramuscular / Oral

3. Mechanism of Action & Pharmacodynamics

Specialist pharmacological agent co-indexed with Deferred to Dedicated Stage 3 Specialist Module (Not in Ch 03–12) (Stage 3 Hospital Critical-Care, Parenteral ICU & UIP Immunisation Module).

4. Therapeutic Indications & Evidence-Supported Uses

  • Specialist hospital, oncology, critical-care, or immunisation indication (Stage 3 Hospital Critical-Care, Parenteral ICU & UIP Immunisation Module).

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Educational Summary: Dosing strictly governed by specialist protocol (BSA mg/m² or weight mg/kg where applicable). Requires specialist oncology/critical-care dosing verification, BSA/weight protocol validation, and CDSCO statutory review prior to Stage 3 publication.

Administration & Meal Timing: Administer strictly under specialist supervision following institutional reconstitution and dilution standards.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Specialist pharmacokinetic and organ-clearance profile; verify renal and hepatic function prior to each cycle/dose.
Metabolism & Biotransformation:
Hepatic/cellular biotransformation per drug class.
Elimination & Renal Adjustment:
Assess baseline CrCl/eGFR before administration.
Hepatic Impairment Considerations:
Assess baseline hepatic panel before administration.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Severe hypersensitivity; specific organ failure or pregnancy/lactation contraindications per approved product label.

Key Clinical Precautions: Requires specialist oncology/critical-care dosing verification, BSA/weight protocol validation, and CDSCO statutory review prior to Stage 3 publication.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Class-specific haematological, gastrointestinal, or infusion-related reactions; monitor closely.
Serious / Dose-Limiting Adverse Effects:
  • Myelosuppression, organ toxicity, or severe hypersensitivity; requires specialist monitoring.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Verify narrow-therapeutic-index, CYP450, QT-prolonging, and immunosuppressive interactions.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Baseline and serial CBC, renal function (SCr/eGFR), liver function tests (AST/ALT/bilirubin), and clinical vitals.

Pharmacist Patient Counselling Points:

  • Counsel patient on indication, schedule adherence, infection/bleeding precautions, and urgent warning signs.

Storage, Stability & Dispensing Safeguards: Verify cold-chain (2°C–8°C) or cytotoxic hazardous-drug handling requirements on official label.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NLEM 2022 • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.